Contracts › 75A50124C00051
75A50124C00051: Execution of the Clinical Method Comparison Study and Regulatory Submission Required to Be Granted Clia-Waiver From the Fda for Febridx Response to Baa-23-100-SOL-00004
Awarded to Lumos Diagnostics, Inc by Office of Assistant Secretary for Preparedness and Response.
$9.2Mobligated
$9.2Mpotential value
30 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50124C00051 |
|---|---|
| Awardee | Lumos Diagnostics, Inc |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN42 Health R&D Services; Health Care - Other; Applied Research |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 25 September 2024 to 30 June 2027 |
| Potential end | 30 June 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record